Recommendations for management of women with suspected uncomplicated lower urinary tract infections (UTIs) include presumptive antibiotics (abx), with or without obtaining a urine culture (UCx). However, with increasing abx resistance, efforts to decrease abx usage are vital. We instituted this study at Columbia University Medical Center Student Health Services (CUMC-SHS) to determine if presumptive treatment of women with suspected uncomplicated UTIs is contributing to unnecessary abx usage.
INTRODUCTION AND OBJECTIVES:
Recommendations for management of women with suspected uncomplicated lower urinary tract infections (UTIs) include presumptive antibiotics (abx), with or without obtaining a urine culture (UCx). However, with increasing abx resistance, efforts to decrease abx usage are vital. We instituted this study at Columbia University Medical Center Student Health Services (CUMC-SHS) to determine if presumptive treatment of women with suspected uncomplicated UTIs is contributing to unnecessary abx usage.
METHODS: We retrospectively reviewed all non-pregnant female patients presenting to CUMC-SHS with UTI symptoms from 12/2016-5/2017 who had UCx sent. Clinical information and presenting symptoms, in addition to office urine dip (Udip) and UCx results, were reviewed. Patients with upper urinary tract involvement or already on abx were excluded. Chi-squared and Fischer's exact tests were performed to compare patients with a positive and negative UCx.
RESULTS: A total of 67 patients were included for analysis. Presenting symptoms included dysuria (59/60, 98%), frequency (41/45, 91%), urgency (27/27, 100%), gross hematuria (17/33, 51%), and suprapubic pain (20/53, 38%). Many patients had symptoms for less than or equal to 24 hours before presentation (32/64, 50%). Office Udip was performed on 33/67 (49%) patients, the results of which were negative in 9%. Dips were positive for leukocytes (88%), blood (79%), and nitrites (18%). All patients were prescribed abx, most commonly nitrofurantoin (82%). Culture results were negative in 29/67 (43%). The most common pathogen on positive UCx was E. coli (84%). There were no significant differences in duration of symptoms, presenting symptoms, or Udip results between patients with a negative UCx and those with a positive UCx.
CONCLUSIONS: Although current recommendations state standard of care for women with suspected uncomplicated UTI is presumptive abx, our study at a health sciences campus found a significant negative UCx rate, representing a cohort of patients who were exposed to abx unnecessarily. Additionally, we found no difference in presenting symptoms or Udip results to help distinguish patients with a positive UCx. It is now current practice at CUMC-SHS to recommend urinary analgesics and to wait for UCx results prior to initiating abx. We believe the findings of this study suggest a cohort in which abx usage can be reduced. (FFP) . A three arm randomized trial was designed to determine whether there are incremental gains in FFP by adding (i) 4-6 mo of short term androgen deprivation therapy (STAD) to PBRT and (ii) the combination of STAD and pelvic lymph node treatment (PLNRT) to PBRT.
METHODS: Patients were randomized to PBRT alone (Arm 1), PBRT þ STAD (Arm 2), and PLNRT þ PBRT þ STAD (Arm 3). The FFP primary endpoint included PSA nadirþ2, clinical failure, or death from any cause. The sample size provided 90% power to detect a 10% absolute FFP improvement at 5 yr in Arm 2 compared to Arm 1 and another 10% improvement in Arm 3 compared to Arm 2 (overall alpha of 0.025). Based on 1191 eligible patents with 5 yr minimum follow-up on the third planned interim analysis for efficacy and futility, stepwise comparisons were made to determine if the Haybittle-Peto (HP) threshold boundary of p < 0.001 (one sided) was crossed. Futility evaluation tested the alternative hypotheses at p < 0.001. Adverse events were graded using CTCAEv3.0.
RESULTS: From 2008-2015, 1792 patients were enrolled. Of these, 1736 were eligible with a median age of 64 yr, black in 13%, baseline Zubrod status of 0 in 93%, seminal vesicle involvement in 15%, pre-radiotherapy PSA of 1.0 ng/ml in 89%, Gleason score <8 in 83%, and pT2 margin positive or pT3 in 72%. Median follow-up for those living is 5.4 yr. For the 1191 patients in the interim analysis cohort, the 5 yr FFP rates for Arms 1, 2, and 3 were 71%, 83% and 89%. When compared to Arm 1, Arm 3 exceeded the HP boundary with a hazard ratio (HR) 0.44 (95% CI: 0.32-0.59). Arm 3 was then compared to Arm 2, yielding a difference of 6% (p [ 0.0063) and an HR of 0.71 (95% CI: 0.51-0.98). In all eligible patients followed for up to 8 years, there were 45, 38 and 25 patients who developed distant metastasis (DM) in Arms 1, 2 and 3. The HR was 0.52 (95% CI: 0.32-0.85) for Arm 3 vs Arm 1 and 0.64 (95% CI: 0.39-1.06) for Arm 3 vs. Arm 2. With IMRT use in 87% of cases, there were no significant differences in late grade 2þ or 3þ renal/GU or GI events; only grade 2þ blood/ bone marrow events attributable to PLNRT were significant (p<0.044).
CONCLUSIONS: These are the first randomized findings to demonstrate that extending salvage radiotherapy to cover the pelvic lymph nodes results in early, meaningful, reductions in progression when combined with STAD. Follow-up of patients will further elucidate the magnitude of the differences in DM and in FFP between arms 2 and 3. 
MP72-02 EXPOSURE TO CYBERKNIFE ADVERTISING IS ASSOCIATED WITH OVER-ESTIMATION OF OBJECTIVE BENEFITS COMPARED WITH OTHER PROSTATE CANCER TREATMENTS
Joseph M Caputo*, New York, NY; Henry J Lee, Bronxville, NY; Bennett Chiles, Elias Hyams, New York, NY INTRODUCTION AND OBJECTIVES: There has been increased direct-to-consumer advertising for Cyberknife (CK), a brand of stereotactic radiotherapy for prostate cancer. Evidence comparing CK with other prostate cancer therapies is limited. We hypothesized that those viewing CK advertisements would have inaccurate impressions regarding its effectiveness and safety. In this study, we evaluated impressions of CK among laypersons exposed to actual advertisements versus factual information/controls. METHODS: Through Qualtrics Panel, a survey management organization, 400 men aged 40-80 were randomly assigned to one of four arms, including a de-identified CK advertisement (ad), the same advertisement with disclaimers (adþd), scientific information obtained from a review of contemporary peer-reviewed literature, and a control. Subjects responded to questions on risks and benefits of CK and their likelihood of pursuing CK versus other treatments. T-tests were utilized to evaluate differences in outcomes for each intervention vs. the control group.
RESULTS: 400 men with largely matched characteristics (Table 1) were included. Compared to controls, those who viewed any of the three interventions were more likely to pursue CK over other treatments (p<0.01), with a greater increase in the ad and adþd groups (Table 2) . Respondents who viewed scientific information were less likely to agree that CK is superior to alternatives regarding side effects of erectile dysfunction and urinary problems. The addition of disclaimers decreased positive impressions of CK regarding side effects, but did not affect impressions of effectiveness (Table 2) . Both ad and adþd respondents were more likely to consider CK superior to other PCa treatments.
CONCLUSIONS: Advertisements regarding CK are misleading and impact laypersons' impressions regarding effectiveness and safety. Direct-to-consumer advertising for cancer care is problematic, and relies on the advertiser and surrounding community to ensure accuracy and transparency. Approximately 30% of patients who undergo radical prostatectomy (RP) harbor aggressive pathologic features and would benefit from early adjuvant radiation therapy (RT). However, less than 10% of this population receive such a treatment, due to concerns of overtreatment and worsening of functional outcomes with early delivery of RT to the pelvis after surgery. We sought to investigate the impact of timing between RP and RT on adverse events rate.
METHODS: Using the Radiation Therapy Oncology Group (RTOG) 9601 trial cohort, we performed post-hoc analysis of 760 men who developed biochemical recurrence after RP, and received subsequent RT (randomized to concomitant bicalutamide vs. placebo). Bowel adverse events (rectal urgency, diarrhea, and hematochezia); bladder adverse events (urinary frequency, dysuria, hematuria, and incontinence); and new onset of erectile dysfunction were documented as acute (<90 days after starting RT) or chronic, at each visit, per trial protocol. Regression analysis tested the impact of
